Under what conditions may a patient be offered experimental treatment?

• A. Experimental treatment may be offered with physician approval only, not IRB
• B. Only with IRB-approved protocols, informed consent that explains risks/benefits/alternatives, and consideration of patient rights and safety
• C. Regardless of protocol, disclosure is not necessary
• D. Experimental treatment can be imposed if it seems beneficial

Answer: (B)

In this area, ethical practice hinges on proper oversight and informed, voluntary participation. Offering an experimental treatment requires two essential safeguards: review by an Institutional Review Board (IRB) of the study protocol to protect subjects, and an informed consent process that clearly explains risks, potential benefits, and available alternatives, with ongoing attention to the patient’s rights and safety. The IRB ensures that the study design minimizes risks, that risks are reasonable in relation to potential benefits, and that subjects are recruited and monitored ethically. Informed consent ensures the patient understands what participation involves, the uncertainties inherent in experimental therapies, possible side effects, and what alternatives exist, and it affirms the patient’s right to decline or withdraw at any time. The patient must have the capacity to consent and participate voluntarily, without coercion or undue pressure.

That’s why the best approach is to offer experimental treatment only under IRB-approved protocols, with comprehensive informed consent that covers risks, benefits, and alternatives, and with careful regard for the patient’s rights and safety. The other options fail to provide the necessary protections: one omits the IRB requirement, another ignores the need for disclosure and consent, and another suggests imposing treatment rather than honoring autonomy and consent.